PTC Therapeutics entered into an asset purchase agreement to acquire Sangamo Therapeutics' assets related to ST-920, a one-time AAV gene therapy candidate for Fabry disease. The transaction involves an upfront payment of $111 million and up to $100 million in contingent milestone payments: $80 million upon FDA accelerated approval and $20 million upon full approval of the biologics license application based on STAAR study data. PTC was selected as the winning bidder in Sangamo's Chapter 11 bankruptcy auction. Closing is subject to Bankruptcy Court approval, with a hearing scheduled for September 10, 2026, and must occur by October 15, 2026. This company operates in the biotechnology industry, developing therapies for rare genetic diseases.

PTC Therapeutics announced it was selected as the winning bidder to acquire ST-920, a BLA-stage one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The acquisition terms include an $111 million upfront payment and up to $100 million in contingent milestone payments: $80 million upon receiving accelerated FDA approval and $20 million upon traditional or full approval. The transaction is subject to definitive documentation, bankruptcy court approval, antitrust review, and customary closing conditions, with expected closure in late Q3 or early Q4 2026. PTC plans to complete a rolling BLA submission for accelerated approval by the end of 2026 based on Phase 1/2 STAAR study data showing favorable renal function effects. PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders.

PTC Therapeutics reported second quarter 2026 financial results on July 30, 2026, posting total revenue of $361 million and net income of $83.5 million. The company raised its full-year 2026 total revenue guidance to $1.18–$1.28 billion and product revenue guidance to $850–$950 million. Sephience generated $151.3 million in Q2 revenue, while the company received a $50 million milestone payment from Novartis for the initiation of the INVEST-HD Phase 3 study. Concurrently, PTC issued $550 million in senior convertible notes due in 2031 and repurchased existing 2026 notes. The company also appointed Hege Sollie-Zetlmayer to its Board of Directors. PTC Therapeutics is a biopharmaceutical company focused on discovering and commercializing medicines for rare genetic disorders.

PTC Therapeutics, Inc. completed a private offering of $550,000,000 in 0.0% Convertible Senior Notes due 2031. The company plans to use approximately $328.8 million of the net proceeds to repurchase $222.0 million of its existing 1.50% Convertible Senior Notes due 2026. PTC Therapeutics, Inc. is a biotechnology company that develops and commercializes therapeutic solutions for life-threatening diseases.

PTC Therapeutics, Inc. priced a $500.0 million offering of 0.00% Convertible Senior Notes due 2031, with an option for initial purchasers to purchase an additional $50.0 million. The company expects to use $328.8 million of the net proceeds to repurchase $222.0 million of its outstanding 1.5% Convertible Senior Notes due 2026. PTC Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases.

Alethia Young resigned from the Board of Directors of PTC Therapeutics, Inc. effective June 8, 2026. She will transition to a consulting role as an advisor to the company through June 8, 2027, receiving a monthly consulting fee of $4,166.67. PTC Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions.